Synlogic Operating Company, Inc.

Synlogic, Inc.

Dean Falb

Jonathan W Kotula

Vincent M Isabella

Paul F Miller

Yves Millet

Adam B Fisher

Sarah Rowe

Suman Machinani

Saurabh Saha

Ning Li

Yossi Dagon

Cami Leigh Anderson

Jose M Lora

David Lubkowicz

Alex Tucker

Paul Miller

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.

Bacteria engineered to reduce hyperphenylalaninemia

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.

Bacteria engineered to treat metabolic diseases

Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.

Bacteria engineered to treat a disease or disorder

Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.

Bacteria for the treatment of disorders

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.

Bacteria engineered to treat diseases associated with hyperammonemia

Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.

Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.

Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier

The disclosure provides genetically engineered bacteria that are capable of reducing excess ammonia and converting ammonia and/or nitrogen into alternate byproducts. The invention also provides pharmaceutical compositions comprising the genetically engineered bacteria, and methods of modulating and treating disorders associated with excess ammonia and inflammation in the gut and the liver, including, for example, hepatic encephalopathy, NASH/NAFLD, HCV, and Huntington's disease, in a subject, comprising administering the engineered bacterium to the subject.

Bacteria engineered to treat liver disease

The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.

Growing community of inventors

Sherborn, MA, United States of America

Dean Falb